IRCT20090701002113N2招募中3 期
Methylene Blue for the Treatment of COVID-19: A Randomized Clinical Trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •>18 yrs old
- •PCR confirmation of COVID-19
- •Severe or critical diseases as: respiratory rate>30 breaths/second, oxygen saturation<94% on room air sea level, lung infiltration of >50%, partial pressure of oxygen/Fraction of inspired oxygen <300 mmHg and/or any individual with respiratory failure, septic shock, and/or multiple organ dysfunction
排除标准
- •G6PD deficiency
- •Severe renal failure (defined as glomerular filtration rate<15 mL/min/1.3m2)
- •History of allergic reaction to drug
- •Patients on serotonergic psychiatric drugs (including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake Inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors), dapsone and different hydroxylamine
- •Organ transplantation recipients
- •Not consenting to enter study
研究者
相似试验
已完成
2 期
Methylene Blue Treatment of COVID-19SARS-CoV2NCT04635605Fondazione Epatocentro Ticino29
已完成
2 期
COVID-19 Methylene Blue Antiviral TreatmentCovid19NCT05004805Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences24
已完成
2 期
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 PatientsSARS-CoV-2 InfectionSafety and EfficacyNCT04621123Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia384
尚未招募
3 期
Comparison of two different medicines named Methylene Blue and Vasopressin for increasing blood pressure in patients with infection and low blood pressureCTRI/2023/06/053979AIIMS New Delhi
进行中（未招募）
1 期
The safety and effectiveness of Methylene Blue MMX® tablets given to patients undergoing screening or surveillance colonoscopy.EUCTR2012-003983-32-DECosmo Technologies Ltd1,270